Orexo announces positive results from pivotal trial for its leading pharmaceutical pipeline asset OX124
· The pivotal trial OX124-002 meets the primary endpoints in the 4-period crossover, comparative bioavailability study in healthy volunteers · OX124 showed a significantly faster and higher absorption of naloxone compared to intramuscular dosing with the injection reference product · OX124 is designed to help in the fight against overdoses caused by the most powerful synthetic opioids that are behind the vast majority of fatal overdoses in the US · Upon approval Orexo will, along with ZUBSOLV® and MODIA™, have the most comprehensive range of treatment options for people suffering